Dietary phosphatidylcholine supplementation attenuates inflammatory mucosal damage in a rat model of experimental colitis

Shock

Volumn 38, Issue 2, 2012, Pages 177-185

  Kovács, Tamás ^a   Varga, Gabriella ^a   Érces, Dániel ^a   Tókés, Tünde ^a   Tiszlavicz, László ^a   Ghyczy, Miklós ^a   Boros, Mihály ^a   Kaszaki, József ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Colitis; fluorescence confocal laser scanning endomicroscopy; inflammation; microcirculation; phosphatidylcholine

Indexed keywords

INTERLEUKIN 6; MYELOPEROXIDASE; NITRIC OXIDE; PHOSPHATIDYLCHOLINE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; XANTHINE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY FLOW; COLITIS; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; IN VIVO STUDY; MALE; MICROCIRCULATION; MICROSCOPY; NONHUMAN; RAT;

ANIMALS; COLITIS; COLON; DIETARY SUPPLEMENTS; HEMODYNAMICS; INTERLEUKIN-6; INTESTINAL MUCOSA; MALE; MICROCIRCULATION; NITRIC OXIDE; PEROXIDASE; PHOSPHATIDYLCHOLINES; RANDOM ALLOCATION; RATS; RATS, WISTAR; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA; XANTHINE DEHYDROGENASE;

EID: 84863988446     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e31825d1ed0     Document Type: Article

References (41)

1. Braus NA, Elliott DE: Advances in the pathogenesis and treatment of IBD. Clin Immunol 132:1-9, 2009.
2. Rainsford KD: Anti-inflammatory drugs in the 21st century. In Harris RE, ed. Inflammation in the Pathogenesis of Chronic Diseases. Vol. 42. The Netherlands: Springer, pp 3-27, 2007.
3. Mourelle M, Guarner F, Malagelada JR: Polyunsaturated phosphatidylcholine prevents stricture formation in a rat model of colitis. Gastroenterology 110: 1093-1097, 1996. (Pubitemid 26113749)
4. Stremmel W, Merle U, Zahn A, Autschbach F, Hinz U, Ehehalt R: Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut 54:966-971, 2005. (Pubitemid 40873911)
5. Erjs G, Kaszaki J, Czobel M, Boros M: Systemic phosphatidylcholine pretreatment protects canine esophageal mucosa during acute experimental biliary reflux. World J Gastroenterol 12:271-279, 2006. (Pubitemid 43336927)
6. Erjs G, Ibrahim S, Siebert N, Boros M, Vollmar B: Oral phosphatidylcholine pretreatment alleviates the signs of experimental rheumatoid arthritis. Arthritis Res Ther 11:43, 2009.
7. Gera L, Varga R, Torok L, Kaszaki J, Szabo A, Nagy K, Boros M: Beneficial effects of phosphatidylcholine during hindlimb reperfusion. J Surg Res 139:45-50, 2007. (Pubitemid 46482562)
8. Ghyczy M, Torday C, Kaszaki J, Szabo A, Czobel M, Boros M: Oral phosphatidylcholine pretreatment decreases ischaemia-reperfusionYinduced methane generation and the inflammatory response in the small intestine. Shock 30:596-602, 2008.
9. Tjkés T, Erjs G, Bebes A, Hartmann P, Várszegi Sz, Varga G, Kaszaki J, Gulya K, Ghyczy M, Boros M: Protective effects of a phosphatidylcholineenriched diet in lipopolysaccharide-induced experimental neuroinflammation in the rat. Shock 36:458-465, 2011.
10. Ehehalt R, Wagenblast J, Erben G, Lehmann WD, Hinz U, Merle U, Stremmel W: Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoelectrosprayYtandem mass spectrometry. Scand J Gastroenterol 39:737-742, 2004. (Pubitemid 39093247)
11. Neurath MF, Fuss I, Pasparakis M, Alexopoulou L, Haralambous S, Meyer zum Büschenfelde KH, Strober W, Kollias G: Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 27: 1743-1750, 1997. (Pubitemid 27302858)
12. Kiss J, Lamarque D, Delchier JC, Whittle BJR: Time-dependent actions of nitric oxide synthase inhibition on colonic inflammation induced by trinitrobenzene sulphonic acid in rats. Eur J Pharmacol 336:219-224, 1997. (Pubitemid 27464868)
13. YueG, Lai PS, Yin K, Sun FF, Nagele RG, Liu X, Linask KK, Wang C, Lin KT, Wong PYK: Colon epithelial cell death in 2,4,6-trinitrobenzenesulfonic acidinduced colitis is associated with increased inducible nitric-oxide synthase expression and peroxynitrite production. J Pharmacol Exp Ther 297:915-925, 2001. (Pubitemid 32472486)
14. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL: Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96:795-803, 1989. (Pubitemid 19057602)
15. Tatsumi Y, Lichtenberger LM: Molecular association of trinitrobenzenesulfonic acid and surface phospholipids in the development of colitis in rats. Gastroenterology 110:780-789, 1996. (Pubitemid 26071846)
16. Deban L, Correale C, Vetrano S, Malesci A, Danese S: Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a jack of all trades. Am J Pathol 172:1457-1466, 2008. (Pubitemid 351793339)
17. Vermeulen W, De Man J, Nullens S, Pelckmans PA, De Winter BY, Morrels TG: The use of colonoscopy to follow the inflammatory time course of TNBS colitis in rats. Acta Gastroenterol Belg 74:304-311, 2011.
18. McLaren WJ, Anikijenko P, Thomas SG, Delaney PM, King RG: In vivo detection of morphological and microvascular changes of the colon in association with colitis using fiberoptic confocal imaging (FOCI). Dig Dis Sci 47:2424-2433, 2002. (Pubitemid 35305447)
19. Kiesslich R, Goetz M, Angus EM, Hu Q, Guan Y, Potten C, Allen T, Neurath M, Shroyer N, Montrose MH, Watson AJM: Identification of epithelial gaps in human small and large intestine by confocal endomicroscopy. Gastroenterology 133:1769-1778, 2007. (Pubitemid 350180813)
20. Riley SA, Mori V, Goldman MJ, Dutt S, Herd ME: Microscopic activity in ulcerative colitis: what does it mean? Gut 32:174-178, 1991.
21. Lichtenberger LM: The hydrophobic barrier properties of gastrointestinal mucus. Annu Rev Physiol 57:565-583, 1995.
22. Fabia R, Ar'Rajab A, Willen R, Andersson R, Ahren B, Larsson K, Bengmark S: Effects of phosphatidylcholine and phosphatidylinositol on acetic-acid-induced colitis in the rat. Digestion 53:35-44, 1992. (Pubitemid 23023005)
23. Grisham MB: Do different animal models of IBD serve different purposes? Inflamm Bowel Dis Suppl 2:132-133, 2008.
24. Hatoum OA, Binion DG, Otterson MF, Gutterman DD,: Acquired microvascular dysfunction in inflammatory bowel disease: loss of nitric oxideYmediated vasodilation. Gastroenterology 125:58-69, 2003. (Pubitemid 36799107)
25. Ehehalt R, Braun A, Karner M, Füllekrug J, Stremmel W: Phosphatidylcholine as a constituent in the colonic mucosal barrierVphysiological and clinical relevance. Biochim Biophys Acta 1801:983-993, 2010.
26. Stremmel W, Hanemann A, Ehehalt R, Karner M, Braun A: Phosphatidylcholine (Lecithin) and the mucus layer: evidence of therapeutic efficacy in ulcerative colitis? Dig Dis 28:490-496, 2010.
27. Braun A, Treede I, Gotthardt D, Tietje A, Zahn A, Ruhwald R, Schoenfeld U, Welsch T, Kienle P, Erben G, et al.: Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflamm Bowel Dis 15:1705-1720, 2009.
28. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, et al.: Mucosal flora in inflammatory bowel disease. Gastroenterology 122:44-54, 2002. (Pubitemid 34049193)
29. Dial EJ, Zayat M, Lopez-Storey M, Tran D, Lichtenberger L: Oral phosphatidylcholine preserves the gastrointestinal mucosal barrier during LPS-induced inflammation. Shock 30:729-733, 2008.
30. Mauch F, Bode G, Ditschuneit H, Malfertheiner P; Demonstration of a phospholipid-rich zone in the human gastric epithelium damaged by Helicobacter pylori. Gastroenterology 105:1698-1704, 1993. (Pubitemid 24002785)
31. Einerhand AW, Renes IB, Makkink MK, van der Sluis M, Buller HA, Dekker J: Role of mucins in inflammatory bowel disease: important lessons from experimental models. Eur J Gastroenterol Hepatol 14:757-765, 2002. (Pubitemid 34753960)
32. Treede I, Braun A, Sparla R, Kuhnel M, Giese T, Turner JR, Anes E, Kulaksiz H, Fullekrug J, Stremmel W, et al.: Anti-inflammatory effects of phosphatidylcholine. J Biol Chem 282:27155-27164, 2007. (Pubitemid 47501946)
33. Tracey KJ: Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 117:289-296, 2007. (Pubitemid 46203953)
34. Ghyczy M, Torday C, Boros M: Simultaneous generation of methane, carbon dioxide, and carbon monoxide from choline and ascorbic acidVa defensive mechanism against reductive stress? FASEB J 17:1124-1126, 2003.
35. Miranda DTSZ, Batista VG, Grando FCC, Paula FMP, Fecio CA, Rubbo GFS, Fernandes LC, Curi R, Nishiyama A: Soy lecithin supplementation alters macrophage phagocytosis and lymphocyte response to concanavalin A: a study in alloxan-induced diabetic rats. Cell Biochem Funct 26:859-865, 2008.
36. Tonks A, Morris RH, Price AJ, Thomas AW, Jones KP, Jackson SK: Dipalmitoylphosphatidylcholine modulates inflammatory functions of monocytic cells independently of mitogen activated protein kinases. Clin Exp Immunol 124:86-94, 2001. (Pubitemid 32479206)
37. Chao W, Spragg RG, Smith RM: Inhibitory effect of porcine surfactant on the respiratory burst oxidase in human neutrophils. Attenuation of p47phox and p67phox membrane translocation as the mechanism. J Clin Invest 96: 2654-2660, 1995.
38. Bordmann G, Rudin W, Favre N: Immunization of mice with phosphatidylcholine drastically reduces the parasitaemia of subsequent Plasmodium chabaudi blood-stage infections. Immunology 94:35-40, 1998. (Pubitemid 28412785)
39. Treede I, Braun A, Jeliaskova P, Giese T, Füllekrug J, Griffiths G, Stremmel W, Ehehalt R: TNF-alphaYinduced up-regulation of pro-inflammatory cytokines is reduced by phosphatidylcholine in intestinal epithelial cells. BMC Gastroenterol 9:53, 2009.
40. Ishikado A, Nishio Y, Yamane K, Mukose A, Morino K, Murakami Y, Sekine O, Makino T, Maegawa H, Kashiwagi A: Soy phosphatidylcholine inhibited TLR4-mediated MCP-1 expression in vascular cells. Atherosclerosis 205:404-412, 2009.
41. Dharmani P, Leung P, Chadee K: Tumor necrosis factor-! and Muc2 mucin play major roles in disease onset and progression in dextran sodium sulphateinduced colitis. PLoS One 6:e25058, 2011.